PMID- 28400070
OWN - NLM
STAT- MEDLINE
DCOM- 20181031
LR  - 20181031
IS  - 1573-2509 (Electronic)
IS  - 0920-9964 (Linking)
VI  - 192
DP  - 2018 Feb
TI  - Decomposing P300 into correlates of genetic risk and current symptoms in 
      schizophrenia: An inter-trial variability analysis.
PG  - 232-239
LID - S0920-9964(17)30188-3 [pii]
LID - 10.1016/j.schres.2017.04.001 [doi]
AB  - BACKGROUND: The P300 event-related potential (ERP) component, which reflects 
      cognitive processing, is a candidate biomarker for schizophrenia. However, the 
      role of P300 in the pathophysiology of schizophrenia remains unclear because 
      averaged P300 amplitudes reflect both genetic predisposition and current clinical 
      status. Thus, we sought to identify which aspects of P300 are associated with 
      genetic risk versus symptomatic status via an inter-trial variability analysis. 
      METHODS: Auditory P300, clinical symptoms, and neurocognitive function 
      assessments were obtained from forty-five patients with schizophrenia, thirty-two 
      subjects at genetic high risk (GHR), thirty-two subjects at clinical high risk 
      (CHR), and fifty-two healthy control (HC) participants. Both conventional 
      averaging and inter-trial variability analyses were conducted for P300, and 
      results were compared across groups using analysis of variance (ANOVA). Pearson's 
      correlation was utilized to determine associations among inter-trial variability 
      for P300, current symptoms and neurocognitive status. RESULTS: Average P300 
      amplitude was reduced in the GHR, CHR, and schizophrenia groups compared with 
      that in the HC group. P300 inter-trial variability was elevated in the CHR and 
      schizophrenia groups but relatively normal in the GHR and HC groups. Furthermore, 
      P300 inter-trial variability was significantly related to negative symptom 
      severity and neurocognitive performance results in schizophrenia patients. 
      CONCLUSIONS: These results suggest that P300 amplitude is an endophenotype for 
      schizophrenia and that greater inter-trial variability of P300 is associated with 
      more severe negative and cognitive symptoms in schizophrenia patients.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Kim, Minah
AU  - Kim M
AD  - Department of Psychiatry, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Lee, Tak Hyung
AU  - Lee TH
AD  - Department of Brain and Cognitive Science, Seoul National University College of 
      Natural Sciences, Seoul, Republic of Korea.
FAU - Kim, Ji-Hun
AU  - Kim JH
AD  - Department of Statistics, Seoul National University, Seoul, Republic of Korea.
FAU - Hong, Hanwoom
AU  - Hong H
AD  - Department of Statistics, Seoul National University, Seoul, Republic of Korea.
FAU - Lee, Tae Young
AU  - Lee TY
AD  - Department of Neuropsychiatry, Seoul National University Hospital, Seoul, 
      Republic of Korea.
FAU - Lee, Youngjo
AU  - Lee Y
AD  - Department of Statistics, Seoul National University, Seoul, Republic of Korea.
FAU - Salisbury, Dean F
AU  - Salisbury DF
AD  - Department of Psychiatry, University of Pittsburgh School of Medicine, 
      Pittsburgh, PA, USA.
FAU - Kwon, Jun Soo
AU  - Kwon JS
AD  - Department of Psychiatry, Seoul National University College of Medicine, Seoul, 
      Republic of Korea; Department of Brain and Cognitive Science, Seoul National 
      University College of Natural Sciences, Seoul, Republic of Korea; Institute of 
      Human Behavioral Medicine, SNU-MRC, Seoul, Republic of Korea. Electronic address: 
      kwonjs@snu.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170408
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
SB  - IM
MH  - Acoustic Stimulation
MH  - Adult
MH  - Analysis of Variance
MH  - Brain Mapping
MH  - Cognition/physiology
MH  - Electroencephalography
MH  - Endophenotypes
MH  - Event-Related Potentials, P300/*physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Neuropsychological Tests
MH  - Psychiatric Status Rating Scales
MH  - Reaction Time/physiology
MH  - Risk Factors
MH  - Schizophrenia/*genetics/*physiopathology
MH  - Statistics as Topic
MH  - Time Factors
MH  - Young Adult
OTO - NOTNLM
OT  - Auditory P300
OT  - Cognitive status
OT  - Endophenotype
OT  - Event-related potential
OT  - Inter-trial variability
OT  - Schizophrenia
EDAT- 2017/04/13 06:00
MHDA- 2018/11/01 06:00
CRDT- 2017/04/13 06:00
PHST- 2016/10/18 00:00 [received]
PHST- 2017/03/15 00:00 [revised]
PHST- 2017/04/01 00:00 [accepted]
PHST- 2017/04/13 06:00 [pubmed]
PHST- 2018/11/01 06:00 [medline]
PHST- 2017/04/13 06:00 [entrez]
AID - S0920-9964(17)30188-3 [pii]
AID - 10.1016/j.schres.2017.04.001 [doi]
PST - ppublish
SO  - Schizophr Res. 2018 Feb;192:232-239. doi: 10.1016/j.schres.2017.04.001. Epub 2017 
      Apr 8.